Nonselective poly(ADP-ribose) polymerase (PARP) inhibitors have shown antitumoral activity, but they are tied to hematotoxicity, most probably due to PARP2 inhibition. Instead, selective PARP inhibitors retain antitumoral activity without risking PARP2-related toxicity.
Researchers from Zymeworks Inc. recently reported preclinical data for ZW-220, an antibody-drug conjugate (ADC) consisting of humanized IgG1 monoclonal antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2, NaPi2b) conjugated to a topoisomerase I inhibitor, being developed for the treatment of cancer.
KAT6 is a histone lysine acetyl transferase involved in the epigenetic regulation of oncogenes and it is often dysregulated in cancer, including breast cancer. Inhibiting KAT6 blocks the transcription of genes such as ESR1 and CCND1 and the use of KAT6 inhibitors together with endocrine therapy and CDK4/6 inhibitor therapy may enhance the effectiveness in cancer.
Antibody-drug conjugates (ADCs) combine monoclonal antibody-targeting capabilities with the cytotoxic effect of conjugated drug payloads. However, there is a need for enhanced strategies to overcome restricted therapeutic window or unacceptable off-target effects.
Evolveimmune Therapeutics Inc. has unveiled EVOLVE-205, a new 2:1 T-cell engager targeting CD20 with integrated affinity-tuned CD3 and CD2 agonists to promote anti-B-cell immunity.
At the Society for Immunotherapy of Cancer (SITC) meeting that ended yesterday in Houston, Dragonfly Therapeutics Inc. reported the first preclinical data on DF-6215, an alpha-active IL-2-Fc, for cancer immunotherapy.
IgA nephropathy is the most common primary glomerulonephritis and contributes to kidney failure. Growing evidence exists that the overactivation of the lectin pathway contributes to the pathogenesis of IgA nephropathy.
The inhibition of hematopoietic progenitor kinase 1 (HPK1), predominantly expressed in immune cells, has proven effective in reducing tumor growth across cancer immune response modulation.
Modified vaccinia Ankara immunization in nonhuman primate models of lethal mpox virus infection, although effective to some extent, has been linked to breakthrough lesions and throat swab viremia.
RSS
